Could This Safe Play Help Eli Lilly & Co. (LLY)?

Page 1 of 2

At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk A/S (ADR) (NYSE:NVO) and Bristol Myers Squibb Co. (NYSE:BMY).

Eli Lilly & Co. (NYSE:LLY)

GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin and insulin. These drugs are generally well-tolerated and carry little risk of hypoglycemia, which makes this class one of the safest diabetes plays.

But how much could this safe play mean for Eli Lilly & Co. (NYSE:LLY)’s overall health?

GLP-1 market

Twice-daily Byetta was the first GLP-1 to market with a Food and Drug Administration approval in 2005. But Victoza quickly took over after its 2010 approval due to a once-weekly dosage.  Victoza has maintained a fairly steady climb ever since. The drug achieved 2012 sales of DKK 9.5 billion (or about $1.6 billion according to current conversion rates), and contributed 39% of the company’s overall sales growth.

Bydureon was brought out last year as a once-weekly version of Byetta. It’s still too early after launch to predict Bydureon’s sales growth, but EvaluatePharma pegged the drug as one of the top five “blockbuster duds” in the past year. Bydureon could see soft sales merely because Victoza got there first and patients don’t want to change treatments.

How does dulaglutide stack up?

Would the once-weekly dulaglutide hold its own in the GLP-1 market — or face a future even less certain than Bydureon’s?

Eli Lilly offered up data from three late-stage trials that showed dulaglutide outperforming Merck’s DPP-4 Januvia, Byetta, and metformin.  Dulaglutide helped patients control blood sugar better than the other drugs and also helped patients lose more weight.

Dulaglutide still has other competitor comparing trials underway. The late-stage trials include Lantus, the company’s own insulin Humalog, and — most importantly — one trial with Victoza. The Victoza trial won’t report until after dulaglutide goes before the FDA for approval later this year. But favorable results could push dulaglutide into a stronger market position.

Other new contenders

Sanofi SA (ADR) (NYSE:SNY)’s Lyxumia received FDA approval in the U.S. and Europe this past February. Lyxumia’s trial results were lackluster and drew criticism for being a Byetta clone. But, as I’ve written previously, Sanofi’s really betting on this drug as a combo therapy for its $7 billion Lantus insulin — a product that loses patent protection in 2015.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!